iBio (IBIO) Competitors $2.19 -0.04 (-1.79%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends IBIO vs. IKNA, CMRX, PDSB, CLSD, QNCX, IMAB, EPIX, AVTE, HOWL, and VTGNShould you be buying iBio stock or one of its competitors? The main competitors of iBio include Ikena Oncology (IKNA), Chimerix (CMRX), PDS Biotechnology (PDSB), Clearside Biomedical (CLSD), Quince Therapeutics (QNCX), I-Mab (IMAB), ESSA Pharma (EPIX), Aerovate Therapeutics (AVTE), Werewolf Therapeutics (HOWL), and Vistagen Therapeutics (VTGN). These companies are all part of the "pharmaceutical products" industry. iBio vs. Ikena Oncology Chimerix PDS Biotechnology Clearside Biomedical Quince Therapeutics I-Mab ESSA Pharma Aerovate Therapeutics Werewolf Therapeutics Vistagen Therapeutics Ikena Oncology (NASDAQ:IKNA) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment, dividends and community ranking. Does the MarketBeat Community prefer IKNA or IBIO? Ikena Oncology received 27 more outperform votes than iBio when rated by MarketBeat users. Likewise, 60.00% of users gave Ikena Oncology an outperform vote while only 42.86% of users gave iBio an outperform vote. CompanyUnderperformOutperformIkena OncologyOutperform Votes3060.00% Underperform Votes2040.00% iBioOutperform Votes342.86% Underperform Votes457.14% Which has more risk & volatility, IKNA or IBIO? Ikena Oncology has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, iBio has a beta of -3.33, suggesting that its share price is 433% less volatile than the S&P 500. Do institutionals & insiders have more ownership in IKNA or IBIO? 75.0% of Ikena Oncology shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 5.9% of Ikena Oncology shares are owned by insiders. Comparatively, 0.6% of iBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has better earnings and valuation, IKNA or IBIO? iBio has lower revenue, but higher earnings than Ikena Oncology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIkena Oncology$9.16M8.96-$68.17M-$1.23-1.38iBio$220K91.08-$24.91MN/AN/A Do analysts recommend IKNA or IBIO? Ikena Oncology presently has a consensus target price of $3.00, indicating a potential upside of 76.47%. iBio has a consensus target price of $4.30, indicating a potential upside of 96.35%. Given iBio's stronger consensus rating and higher possible upside, analysts clearly believe iBio is more favorable than Ikena Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ikena Oncology 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50iBio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is IKNA or IBIO more profitable? Ikena Oncology's return on equity of -36.88% beat iBio's return on equity.Company Net Margins Return on Equity Return on Assets Ikena OncologyN/A -36.88% -33.08% iBio N/A -78.53%-41.79% Does the media favor IKNA or IBIO? In the previous week, Ikena Oncology had 3 more articles in the media than iBio. MarketBeat recorded 3 mentions for Ikena Oncology and 0 mentions for iBio. iBio's average media sentiment score of 1.00 beat Ikena Oncology's score of 0.76 indicating that iBio is being referred to more favorably in the news media. Company Overall Sentiment Ikena Oncology Positive iBio Positive SummaryIkena Oncology beats iBio on 9 of the 15 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get iBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBIO vs. The Competition Export to ExcelMetriciBioPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$20.40M$6.48B$5.07B$19.96BDividend YieldN/A8.11%4.99%3.49%P/E RatioN/A4.4283.5735.39Price / Sales91.08375.031,220.3018.01Price / CashN/A52.5939.4621.27Price / Book1.1310.126.934.58Net Income-$24.91M$153.61M$119.12M$985.93M7 Day Performance0.23%-2.00%-1.83%0.45%1 Month Performance-28.43%-7.47%-3.64%1.05%1 Year PerformanceN/A31.80%31.64%24.67% iBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBIOiBio1.6995 of 5 stars$2.19-1.8%$4.30+96.3%N/A$20.40M$220,000.000.00100Positive NewsGap UpIKNAIkena Oncology3.4984 of 5 stars$1.70+1.2%$3.00+76.5%-0.6%$81.07M$9.16M0.0070CMRXChimerix4.5147 of 5 stars$0.88flat$8.50+865.9%-12.0%$79.14M$320,000.000.0072Analyst ForecastPDSBPDS Biotechnology1.8427 of 5 stars$2.03-3.3%$12.33+509.1%-67.9%$78.37MN/A0.0020CLSDClearside Biomedical3.0181 of 5 stars$1.05+1.9%$5.33+407.9%+8.1%$78.12M$8.23M-2.3330Analyst RevisionQNCXQuince Therapeutics2.8745 of 5 stars$1.84+4.0%$8.50+362.0%+109.1%$77.88MN/A0.0060IMABI-Mab2.5473 of 5 stars$0.98+3.2%$8.00+716.3%-37.6%$77.61M$3.89M0.0034Gap UpEPIXESSA Pharma2.7825 of 5 stars$1.73-0.6%$11.67+574.4%-68.0%$77.20MN/A-2.7950AVTEAerovate Therapeutics1.709 of 5 stars$2.66-0.4%$2.25-15.4%-81.7%$77.10MN/A0.0051Positive NewsHOWLWerewolf Therapeutics3.4171 of 5 stars$1.64-1.8%$12.00+631.7%-33.6%$74.42M$19.94M0.0040Analyst ForecastVTGNVistagen Therapeutics3.774 of 5 stars$2.61-2.2%$15.00+474.7%-25.4%$74.34M$1.06M0.0040Positive News Related Companies and Tools Related Companies IKNA Alternatives CMRX Alternatives PDSB Alternatives CLSD Alternatives QNCX Alternatives IMAB Alternatives EPIX Alternatives AVTE Alternatives HOWL Alternatives VTGN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:IBIO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IBIO Stock Alerts